Assessing Liquidia (LQDA) Valuation After A Sharp 1 Year Shareholder Return
Liquidia (LQDA) has drawn fresh attention after a strong past 3 months, with the stock showing a very large 1 year total return. Investors are weighing this performance against its rare cardiopulmonary disease focus.
See our latest analysis for Liquidia.
The share price has settled at US$61.86 after a steep 30 day share price return of 62.15% and a 90 day share price return close to 100%. The 1 year total shareholder return is also very large, suggesting recent momentum has sharply reshaped how the market prices Liquidia’s rare disease pipeline and associated risks.
If Liquidia’s run has you thinking about where else high conviction ideas might emerge next, this could be a good moment to scan 37 healthcare AI stocks
With Liquidia posting a very large 1 year total return and trading close to analyst price targets, yet still at a sizeable modelled intrinsic discount, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?
Most Popular Narrative: 40.6% Overvalued
The most followed narrative pegs Liquidia’s fair value at $44.00, which sits well below the recent $61.86 close, and hinges on aggressive growth expectations.
• Analysts are assuming Liquidia's revenue will grow by 118.1% annually over the next 3 years.
• Analysts assume that profit margins will increase from -179.3% today to 41.8% in 3 years time.
Curious what kind of revenue curve and margin profile could support that valuation gap and still land on a mid teens earnings multiple by 2029? The narrative leans on a sharp swing from losses to strong profitability and a material step up in earnings power over time.
Result: Fair Value of $44.00 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, those assumptions could quickly look stretched if payer contracts do not translate prescriptions into paid revenue as expected or if the expanded manufacturing footprint remains underused.
Find out about the key risks to this Liquidia narrative.
Another View: Cash Flows Tell a Different Story
The popular narrative tags Liquidia as 40.6% overvalued at a fair value of $44.00, yet Simply Wall St’s DCF model points to a very different conclusion. With the stock at $61.86 and an estimated future cash flow value of $295.50, the DCF model implies a very large upside gap.
For you, that raises a simple question: are analysts too cautious, or is the DCF leaning too heavily on optimistic cash flow paths that may never materialize?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Liquidia for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
After weighing a bullish DCF and a more cautious fair value, the real question is how you interpret the mix of risks and rewards here. To explore this in more detail, take a closer look at the 3 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Liquidia has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted stock searches tailored to different strengths and preferences.
- Target potential value opportunities by scanning 46 high quality undervalued stocks that combine solid fundamentals with appealing pricing signals.
- Prioritise resilience by reviewing 62 resilient stocks with low risk scores that score well on financial health and lower risk profiles.
- Spot early-stage potential by checking the screener containing 22 high quality undiscovered gems before other investors start paying closer attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com